Prime Medicine, Inc. (NASDAQ:PRME) ranks among the overlooked penny stocks to buy right now, supported by strong upside ...

Explore the revolutionary potential of biotechnology and gene editing, alongside crucial ethical considerations and ...

A Surrey family is racing against time to raise enough money for a gene-editing procedure that could save their ...

Recent data published in NEJM demonstrates that CRISPR gene-editing therapy achieves complete clinical efficacy endpoints in ...

Is NTLA a good stock to buy? We came across a bullish thesis on Intellia Therapeutics, Inc. on Markman Capital Insight’s Substack. In this article, we will summarize the bulls’ thesis on NTLA.

After weeks inside TriStar Centennial Children’s Hospital in Nashville, he was expected to walk out on Thursday, July 2, 2026 ...

Researchers have spent decades—and billions of dollars—sequencing animal and crop genomes, but fungi have historically been the forgotten middle child of genomics, only noticed when they're ruining ...

A single infusion of an experimental gene-editing therapy reduced LDL cholesterol in patients with familial ...

Amy Scott, host of the podcast "How We Survive," reports on a company that's working on de-extinction innovation to try and ...

Rickey Buggs, who has lived with sickle cell since infancy, became the hospital’s first commercial patient to receive the ...

The FDA on Wednesday expanded the approval for exagamglogene autotemcel (exa-cel, Casgevy) in severe sickle cell disease with ...

Scientists have poured decades and billions of dollars into reading the genomes of animals and crops. Fungi mostly got left behind. The kingdom tends to earn attention only when it spoils bread or ...